- Positive results reported from the phase 3 AVATAR study using Anavex 2-73 for the treatment of adult females with Rett Syndrome; Primary endpoint of RSBQ AUC met with statistical significance.
- Positive results from phase 3 AVATAR study, along with prior positive results from phase 2, being taken to FDA to discuss potential approval pathway for patients with Rett Syndrome.
- Results from the phase 3 study, using Anavex 2-73 for the treatment of patients with Alzheimer's Disease are expected 2nd half of 2022.
- The global Alzheimer's market is expected to reach $25 billion by 2027.
For further details see:
Anavex: Misunderstood Data And Possible Positive FDA Meeting Can Lead To Great Trade Opportunity